Kopp Family Office, LLC Long-Term Concentrated

CIK: 0001683689 · Show all filings

Period: Q2 2020 (← Previous) (Next →)

Filing Date: Aug 17, 2020

Total Value ($000): $185,093 (100.0% shares, 0.0% debt)

Holdings (5)

NEO NeoGenomics Inc. 78.0%

Value ($000) $144,424 Shares 4,661,835 Est. Cost $23.81 Unrealized +16.4%

— Horizon Therapeutics Public Limited Company 9.5%

Value ($000) $17,581 Shares 316,325 Est. Cost $55.58 Unrealized —

VCEL Vericel Corporation 8.1%

Value ($000) $14,955 Shares 1,082,155 Est. Cost $14.73 Unrealized -8.1%

FIVN Five9, Inc. 3.8%

Value ($000) $7,082 Shares 63,995 Est. Cost $76.95 Unrealized +26.5%

— Intersect ENT Inc. 0.6%

Value ($000) $1,051 Shares 77,630 Est. Cost $23.02 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
NEO	NeoGenomics Inc.	4,661,835	$144,424	78.0%	$23.81	+16.4%	COM NEW	64049M209
—	Horizon Therapeutics Public Limited Company	316,325	$17,581	9.5%	$55.58	—	SHS	G46188101
VCEL	Vericel Corporation	1,082,155	$14,955	8.1%	$14.73	-8.1%	COM	92346J108
FIVN	Five9, Inc.	63,995	$7,082	3.8%	$76.95	+26.5%	COM	338307101
—	Intersect ENT Inc.	77,630	$1,051	0.6%	$23.02	—	COM	46071F103